Published in Hepatology on April 05, 2013
Relating serum GGT to ALT activity enhances its predictability on treatment outcome in chronic hepatitis C. Hepatology (2014) 0.97
Reduction of microRNA 122 expression in IFNL3 CT/TT carriers and during progression of fibrosis in patients with chronic hepatitis C. J Virol (2014) 0.91
Gamma-Glutamyltransferase: A Predictive Biomarker of Cellular Antioxidant Inadequacy and Disease Risk. Dis Markers (2015) 0.84
Interferon lambda polymorphisms associate with body iron indices and hepatic expression of interferon-responsive long non-coding RNA in chronic hepatitis C. Clin Exp Med (2016) 0.83
Genetic polymorphisms of vitamin D pathway predict antiviral treatment outcome in slow responder naïve patients with chronic hepatitis C. PLoS One (2013) 0.78
Association of IFNL3 rs12979860 and rs8099917 with biochemical predictors of interferon responsiveness in chronic hepatitis C virus infection. PLoS One (2013) 0.78
Serum galectin-3 levels in children with chronic hepatitis B infection and inactive hepatitis B carriers. Med Sci Monit (2015) 0.76
Relevance of baseline viral genetic heterogeneity and host factors for treatment outcome prediction in hepatitis C virus 1b-infected patients. PLoS One (2013) 0.76
Albumin to gamma-glutamyltransferase ratio as a prognostic indicator in intrahepatic cholangiocarcinoma after curative resection. Oncotarget (2017) 0.75
Pretreatment prediction of the outcome of response-guided peginterferon-α and ribavirin therapy for chronic hepatitis C. J Gastroenterol Hepatol (2014) 0.75
Correcting for Measurement Error in Time-Varying Covariates in Marginal Structural Models. Am J Epidemiol (2016) 0.75
Association of serum gamma-glutamyl transferase with treatment outcome in chronic hepatitis B patients. World J Gastroenterol (2015) 0.75
Reply: To PMID 23258530. Hepatology (2014) 0.75
Gamma-glutamyl transpeptidase to platelet ratio index is a good noninvasive biomarker for predicting liver fibrosis in Chinese chronic hepatitis B patients. J Int Med Res (2016) 0.75
Lack of Association between Hepatitis C Virus core Gene Variation 70/91aa and Insulin Resistance. Int J Mol Sci (2017) 0.75
Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature (2009) 26.47
Prolonged therapy of advanced chronic hepatitis C with low-dose peginterferon. N Engl J Med (2008) 9.33
Identification of chronic hepatitis C patients without hepatic fibrosis by a simple predictive model. Hepatology (2002) 6.92
Evolution of the HALT-C Trial: pegylated interferon as maintenance therapy for chronic hepatitis C in previous interferon nonresponders. Control Clin Trials (2004) 3.46
Elevated serum alanine aminotransferase and gamma-glutamyltransferase and mortality in the United States population. Gastroenterology (2008) 2.63
Gamma-glutamyltransferase is associated with incident vascular events independently of alcohol intake: analysis of the British Women's Heart and Health Study and Meta-Analysis. Arterioscler Thromb Vasc Biol (2007) 2.45
Prospective study of serum gamma-glutamyltransferase and risk of NIDDM. Diabetes Care (1998) 2.42
Regulation of cellular glutathione. Am J Physiol (1989) 2.26
Alanine aminotransferase, gamma-glutamyltransferase, and incident diabetes: the British Women's Heart and Health Study and meta-analysis. Diabetes Care (2009) 2.23
Disease progression and hepatocellular carcinogenesis in patients with chronic viral hepatitis: a prospective observation of 2215 patients. J Hepatol (1998) 2.21
Ultrasonographic hepatic steatosis increases prediction of mortality risk from elevated serum gamma-glutamyl transpeptidase levels. Hepatology (2009) 1.97
Predicting cirrhosis in patients with hepatitis C based on standard laboratory tests: results of the HALT-C cohort. Hepatology (2005) 1.93
Patatin-like phospholipase domain-containing 3 I148M polymorphism, steatosis, and liver damage in chronic hepatitis C. Hepatology (2011) 1.70
Joint effects of coffee consumption and serum gamma-glutamyltransferase on the risk of liver cancer. Hepatology (2008) 1.59
A predictive model of response to peginterferon ribavirin in chronic hepatitis C using classification and regression tree analysis. Hepatol Res (2010) 1.58
Gamma glutamyltransferase and long-term survival: is it just the liver? Clin Chem (2007) 1.56
Meta-analyses of FibroTest diagnostic value in chronic liver disease. BMC Gastroenterol (2007) 1.49
Disturbances of electrolytes and blood chemistry in acute alcohol intoxication. Wien Klin Wochenschr (2005) 1.47
Gamma-glutamyl transpeptidase in glutathione biosynthesis. Methods Enzymol (2005) 1.45
Predicting clinical and histologic outcomes based on standard laboratory tests in advanced chronic hepatitis C. Gastroenterology (2009) 1.35
A prospective study of the rate of progression in compensated, histologically advanced chronic hepatitis C. Hepatology (2011) 1.33
Coffee consumption and decreased serum gamma-glutamyltransferase and aminotransferase activities among male alcohol drinkers. Int J Epidemiol (1998) 1.31
Association between serum gamma-glutamyltransferase and C-reactive protein. Atherosclerosis (2005) 1.31
Gamma-glutamyltransferase and risk of cancer in a cohort of 545,460 persons - the Swedish AMORIS study. Eur J Cancer (2011) 1.29
Unexpected effects of coffee consumption on liver enzymes. Eur J Epidemiol (1993) 1.25
Structural, functional, and clinical aspects of gamma-glutamyltransferase. CRC Crit Rev Clin Lab Sci (1980) 1.21
Evolution of hepatic steatosis in patients with advanced hepatitis C: results from the hepatitis C antiviral long-term treatment against cirrhosis (HALT-C) trial. Hepatology (2009) 1.18
Elevated serum gamma-glutamyltransferase activity is associated with increased risk of mortality, incident type 2 diabetes, cardiovascular events, chronic kidney disease and cancer - a narrative review. Clin Chem Lab Med (2010) 1.17
Relation of IL28B gene polymorphism with biochemical and histological features in hepatitis C virus-induced liver disease. PLoS One (2012) 1.09
Diabetes mellitus in chronic hepatitis B and C: prevalence and potential association with the extent of liver fibrosis. J Viral Hepat (2006) 1.07
Role of gamma-glutamyl transferase activity in patients with chronic hepatitis C virus infection. J Gastroenterol Hepatol (2004) 1.05
Prooxidant reactions promoted by soluble and cell-bound gamma-glutamyltransferase activity. Methods Enzymol (2005) 1.04
Redox regulation of gamma-glutamyl transpeptidase. Am J Respir Cell Mol Biol (2009) 1.03
Determinants of gamma-glutamyltransferase: positive interaction with alcohol and body mass index, negative association with coffee. Am J Epidemiol (1997) 1.02
A histopathological study of alcoholics with chronic HCV infection: comparison with chronic hepatitis C and alcoholic liver disease. Liver (1995) 1.00
Is there any non-invasive marker replace the needle liver biopsy predictive for liver fibrosis, in patients with chronic hepatitis? Hepatogastroenterology (2009) 0.96
Differential enhancement of gamma-glutamyl transpeptidase and gamma-glutamylcysteine synthetase by tert-butylhydroquinone in rat lung epithelial L2 cells. Am J Respir Cell Mol Biol (1996) 0.94
Gamma-glutamyl transferase (GGT) as an independent predictive factor of sustained virologic response in patients with hepatitis C treated with interferon-alpha and ribavirin. J Clin Gastroenterol (2005) 0.93
Gamma-glutamyltransferase, general and cause-specific mortality in 19,000 construction workers followed over 20 years. J Hepatol (2011) 0.91
Serum gamma-glutamyl transpeptidase is a determinant of insulin resistance independently of adiposity in Pima Indian children. J Clin Endocrinol Metab (2006) 0.91
The determination of GGT is the most reliable predictor of nonresponsiveness to interferon-alpha based therapy in HCV type-1 infection. J Gastroenterol (2011) 0.90
Gamma-glutamyltransferase and rapid virological response as predictors of successful treatment with experimental or standard peginterferon-alpha-2b in chronic hepatitis C non-responders. Liver Int (2007) 0.88
Long-term follow-up of chronic hepatitis C in patients diagnosed at a tertiary-care center. J Hepatol (2001) 0.86
Comparison of the serum ferritin and percentage of transferrin saturation as exposure markers of iron-driven oxidative stress-related disease outcomes. Am Heart J (2006) 0.86
Predictors of response to chronic hepatitis C treatment. Ann Hepatol (2010) 0.82
Gamma-glutamyltranspeptidase in predicting sustained virological response in individuals with chronic hepatitis C. Hepatogastroenterology (2011) 0.81
Clinical, virologic and pathologic significance of elevated serum gamma-glutamyl transpeptidase in patients with chronic hepatitis C. Zhonghua Yi Xue Za Zhi (Taipei) (2000) 0.79
Studies of gamma-glutamyl transferase in alpha-1 antitrypsin deficiency. COPD (2010) 0.78
Gamma-glutamyltransferase in fine-needle liver biopsies of subjects with chronic hepatitis C. J Viral Hepat (2005) 0.78
Prolonged therapy of advanced chronic hepatitis C with low-dose peginterferon. N Engl J Med (2008) 9.33
Des-gamma-carboxy prothrombin and alpha-fetoprotein as biomarkers for the early detection of hepatocellular carcinoma. Gastroenterology (2009) 4.90
Peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who have failed prior treatment. Gastroenterology (2004) 4.27
Prevalence of estimated GFR reporting among US clinical laboratories. Am J Kidney Dis (2008) 3.55
Evolution of the HALT-C Trial: pegylated interferon as maintenance therapy for chronic hepatitis C in previous interferon nonresponders. Control Clin Trials (2004) 3.46
Protection from obesity and diabetes by blockade of TGF-β/Smad3 signaling. Cell Metab (2011) 2.73
Serum alpha-fetoprotein levels in patients with advanced hepatitis C: results from the HALT-C Trial. J Hepatol (2005) 2.63
Maintenance peginterferon therapy and other factors associated with hepatocellular carcinoma in patients with advanced hepatitis C. Gastroenterology (2010) 2.47
Association of IL28B genotype with fibrosis progression and clinical outcomes in patients with chronic hepatitis C: a longitudinal analysis. Hepatology (2013) 2.17
Relationship of serum fibrosis markers with liver fibrosis stage and collagen content in patients with advanced chronic hepatitis C. Hepatology (2008) 2.02
Predicting cirrhosis in patients with hepatitis C based on standard laboratory tests: results of the HALT-C cohort. Hepatology (2005) 1.93
Serum fibrosis markers are associated with liver disease progression in non-responder patients with chronic hepatitis C. Gut (2010) 1.78
Impact of reducing peginterferon alfa-2a and ribavirin dose during retreatment in patients with chronic hepatitis C. Gastroenterology (2006) 1.76
DNA polymorphisms and response to treatment in patients with chronic hepatitis C: results from the HALT-C trial. J Hepatol (2008) 1.71
Use of complementary and alternative medicine in patients with liver disease. Am J Gastroenterol (2002) 1.57
Predicting clinical and histologic outcomes based on standard laboratory tests in advanced chronic hepatitis C. Gastroenterology (2009) 1.35
A prospective study of the rate of progression in compensated, histologically advanced chronic hepatitis C. Hepatology (2011) 1.33
Specificity characteristics of 7 commercial creatinine measurement procedures by enzymatic and Jaffe method principles. Clin Chem (2011) 1.32
Cardiopulmonary complications leading to premature deaths in adult patients with sickle cell disease. Am J Hematol (2010) 1.28
Safety and efficacy of pegylated interferon alpha-2a and ribavirin for the treatment of hepatitis C in patients with thalassemia. Haematologica (2008) 1.26
Frequency of elevated hepatocellular carcinoma (HCC) biomarkers in patients with advanced hepatitis C. Am J Gastroenterol (2011) 1.20
Angiotensin II overcomes strain-dependent resistance of rapid CKD progression in a new remnant kidney mouse model. Kidney Int (2010) 1.16
HCV RNA detection by TMA during the hepatitis C antiviral long-term treatment against cirrhosis (Halt-C) trial. Hepatology (2006) 1.13
Prognostic value of Ishak fibrosis stage: findings from the hepatitis C antiviral long-term treatment against cirrhosis trial. Hepatology (2010) 1.12
Quantitative liver function tests improve the prediction of clinical outcomes in chronic hepatitis C: results from the Hepatitis C Antiviral Long-term Treatment Against Cirrhosis Trial. Hepatology (2012) 1.12
Fibrosis progression in chronic hepatitis C: morphometric image analysis in the HALT-C trial. Hepatology (2009) 1.08
Hepatic involvement and portal hypertension predict mortality in chronic granulomatous disease. Gastroenterology (2008) 1.06
Associations among clinical, immunological, and viral quasispecies measurements in advanced chronic hepatitis C. Hepatology (2005) 1.05
Effect of HCV RNA suppression during peginterferon alfa-2a maintenance therapy on clinical outcomes in the HALT-C trial. Gastroenterology (2009) 1.03
Coffee consumption is associated with response to peginterferon and ribavirin therapy in patients with chronic hepatitis C. Gastroenterology (2011) 1.02
Blunted cytopenias and weight loss: new correlates of virologic null response to re-treatment of chronic hepatitis C. Clin Gastroenterol Hepatol (2008) 0.98
Excess mortality in patients with advanced chronic hepatitis C treated with long-term peginterferon. Hepatology (2011) 0.98
Low 24-hour adiponectin and high nocturnal leptin concentrations in a case-control study of community-dwelling premenopausal women with major depressive disorder: the Premenopausal, Osteopenia/Osteoporosis, Women, Alendronate, Depression (POWER) study. J Clin Psychiatry (2010) 0.96
Complementary and alternative medicine (CAM) for the treatment of chronic hepatitis B and C: a review. Antivir Ther (2007) 0.93
Interpretation of positive transcription-mediated amplification test results from polymerase chain reaction-negative samples obtained after treatment of chronic hepatitis C. Hepatology (2008) 0.91
Cognitive function does not worsen during pegylated interferon and ribavirin retreatment of chronic hepatitis C. Hepatology (2007) 0.89
Inactivation of microbial arginine deiminases by L-canavanine. J Am Chem Soc (2008) 0.89
Increased reticulocytosis during infancy is associated with increased hospitalizations in sickle cell anemia patients during the first three years of life. PLoS One (2013) 0.88
Cognitive reserve and neuropsychological functioning in patients infected with hepatitis C. J Int Neuropsychol Soc (2007) 0.87
A randomized phase II trial of Arginine Butyrate with standard local therapy in refractory sickle cell leg ulcers. Br J Haematol (2010) 0.87
Reticulocytosis and anemia are associated with an increased risk of death and stroke in the newborn cohort of the Cooperative Study of Sickle Cell Disease. Am J Hematol (2014) 0.86
Predicting clinical outcomes using baseline and follow-up laboratory data from the hepatitis C long-term treatment against cirrhosis trial. Hepatology (2011) 0.85
Infusion of hemolyzed red blood cells within peripheral blood stem cell grafts in patients with and without sickle cell disease. Blood (2012) 0.81
Reduction in Hepatic Inflammation Is Associated With Less Fibrosis Progression and Fewer Clinical Outcomes in Advanced Hepatitis C. Am J Gastroenterol (2012) 0.78
More severe parenchymal injury in chronic hepatitis C acquired by recent injection drug use. J Clin Gastroenterol (2005) 0.76
Automated summaries of serious adverse events in the hepatitis C antiviral long-term treatment against cirrhosis trial. Clin Trials (2009) 0.76
Reply: To PMID 23703931. Hepatology (2014) 0.75
Processes to manage analyses and publications in a phase III multicenter randomized clinical trial. Trials (2014) 0.75